Clinical Trial Update: Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases

View source ↗

Summary

An ongoing clinical trial is evaluating osimertinib in combination with intracranial stereotactic radiotherapy for EGFR-mutant non-small cell lung cancer with s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)

Snippet

Sponsor: Fudan University | Conditions: NSCLC (Advanced Non-small Cell Lung Cancer), Brain Metastases From Non-small Cell Lung Cancer (NSCLC) | Status: ACTIVE_NOT_RECRUITING